Key result
Microaxial flow pump in cardiogenic shock carries a ~59% 30-day rate of major bleeding.
Why the study?
Temporary mechanical circulatory support for cardiogenic shock carries high risks of major bleeding and arterial thrombotic events that may exceed clinical trial rates in real-world practice. Characterizing the real-world incidence, timing, and risk factors of these complications is needed to inform time-sensitive strategies that balance bleeding and ischemic risks.
What are the real-world incidence, temporal patterns, and risk factors for major bleeding and arterial thrombotic events in patients with cardiogenic shock supported by a microaxial flow pump?
Cohort (n=204)
Yes
What are the real-world incidence, temporal patterns, and risk factors for major bleeding and arterial thrombotic events in patients with cardiogenic shock supported by a microaxial flow pump?
In cardiogenic shock patients on microaxial flow pump support, major bleeding occurs frequently and early (median 3 days) while arterial thrombotic events occur less frequently and later (median 10 days), suggesting a need for dynamic, time-sensitive antithrombotic strategies rather than uniform anticoagulation targets.
Answers are grounded in this paper and cite their sources.
Major bleeding risk warrants cautious early antithrombotic management in microaxial-supported shock; leaves optimal dynamic strategies open for prospective trials.
Background Use of temporary mechanical circulatory support (tMCS) for cardiogenic shock (CS) is associated with high risks of major bleeding and arterial thrombotic events (ATEs), potentially exceeding clinical trial rates in real-world practice. Characterizing the incidence and temporal patterns of these complications may provide opportunities for time-sensitive strategies to balance bleeding and ischemic risk. Objective Assessment of real-world incidence, timing, and risks for major bleeding and ATE with tMCS for CS. Methods Prospective data from patients with CS supported by microaxial flow pump (mAFP), with or without veno-arterial extracorporeal membrane oxygenation (VA-ECMO), at two quaternary shock centres, were analysed. Results Among 204 patients with CS (predominantly Society for Cardiovascular Angiography and Interventions stages D-E), major bleeding was frequent (59%), occurring early after tMCS implantation (median 3 days), whereas ATEs were less common (14%), predominantly occurring later (median 10 days) with prolonged mAFP support. At 30 days, cumulative incidences of major bleeding and ATEs were 59.1% and 13.4%, respectively, versus 14.8% and 37.1% for competing death. Conventional coagulation assays did not differentiate patients developing major bleeding or ATEs. Major bleeding was associated with ECMELLA support and dual antiplatelet therapy, while ATEs associated with prolonged mAFP support and elevated fibrinogen. Conclusion In patients with CS supported by tMCS, major bleeding was frequent and occurred earlier, whereas ATEs were less frequent, occurring later, among survivors receiving prolonged support. Neither complication was reflected by conventional coagulation assays. These distinct temporal patterns could inform more dynamic, individualised antithrombotic management to mitigate bleeding and thrombotic risks.
No takes yet. Share an insight, caveat, or question.
Galusko et al. (2026) conducted a cohort in Cardiogenic shock (n=204). Microaxial flow pump (mAFP) support with or without VA-ECMO (ECMELLA) vs. mAFP support alone (for ECMELLA comparisons) was evaluated on Major bleeding (BARC ≥3) at 30 days (95% CI 52.1-65.5). Microaxial flow pump support in cardiogenic shock had a 59.1% 30-day incidence of major bleeding (median 3 days) versus 13.4% for arterial thrombotic events (median 10 days).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: